Blockchain Adds a Trusted Data Layer in Pharma Manufacturing

Blockchain in pharma manufacturing could provide a shared, end-to-end, tamper-resistant record of production, quality, and supply-chain activity. The strongest value will come from improving traceability, data integrity, auditability, and coordination across fragmented pharmaceutical operations. 

Image

Blockchain Matters in Pharma Manufacturing

Pharmaceutical manufacturing depends on data moving between manufacturing sites, quality teams, suppliers, contract manufacturers, laboratories, logistics providers, and regulators. Each crucial part may operate under different systems with different databases and processes.

That creates the basic challenge of how to establish that critical information remains complete, authentic, and unaltered across multiple parties.

A large 2022 systematic review of blockchain applications across the pharmaceutical industry provides an indication of where researchers have previously focused their attention. 

Counterfeit-drug prevention was the largest application category. It appeared in 45% of studies, while tracking and tracing featured in 37% of studies, and safety and security and product distribution in 21% and 18% of studies, respectively.

*Categories could overlap, so percentages do not total 100%.

The review also identified applications involving data governance, data quality, pharmaceutical turnover, and prescription monitoring, highlighting that product quality does not begin when a batch enters a production line. Raw-material provenance, supplier activity, processing, laboratory testing, batch release, storage, and distribution all contribute to the product’s history.

Blockchain could provide a shared, auditable, and tamper-resistant record of these events.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

The Latest Evidence on Blockchain in Pharma Manufacturing

A recent review in Pharmaceutical Research expands the discussion of blockchain in pharma manufacturing beyond supply-chain traceability.

Blockchain use was analysed across drug discovery, formulation development, manufacturing, distribution, clinical research, and healthcare, including its integration with artificial intelligence and the Internet of Things.

The review found that blockchain can strengthen data integrity, immutability, traceability, transparency, and security across pharmaceutical workflows.

Additionally, several potentially significant operational effects were identified:

• 20–30% reduction in multi-site data reconciliation time
• 15–25% improvement in manufacturing and quality-control operational efficiency
• Approximately 30% reduction in compliance-documentation errors
• More than 60% improvement in recall efficiency
• Approximately 40% reduction in counterfeit-medicine circulation

Proper blockchain use in pharmaceutical manufacturing resulted in up to 55% improvements in operational efficiency and 50% reductions in logistics and compliance-related costs when integrated with AI and IoT.

These numbers need context. Because results from a single controlled, large-scale pharmaceutical manufacturing deployment are not available, the figures should not be treated as guaranteed savings or industry-wide benchmarks.

However, the evidence strongly points to blockchain as a valuable technology in pharma manufacturing, while adoption decisions still require testing against specific manufacturing environments, processes, and regulatory requirements.

Where Blockchain Could Strengthen Pharma Manufacturing Most

The value of blockchain in pharma manufacturing is not simply that information becomes decentralised.

The more important proposition for blockchain is that authorised participants can establish a common record of what happened, when it happened, and which organisation or system recorded it.

Image

Several manufacturing-use cases stand out:

Batch and material traceability

A blockchain-based architecture could connect information about raw materials, manufacturing stages, laboratory testing, batch release, and subsequent movement.

That could strengthen end-to-end product provenance and make investigations more efficient when discrepancies occur.

The 2026 review showed a greater than 60% improvement in recall efficiency. If reliable batch and transaction histories are available across multiple parties, manufacturers could potentially identify affected products more rapidly and establish where they entered the supply chain.

However, batch and material traceability completely depends on the quality of the information entering the blockchain. An immutable record cannot correct inaccurate source data.

Data integrity and audit trails

Manufacturing environments generate enormous volumes of regulated information. Batch records, laboratory results, equipment data, quality events, and supply-chain transactions all need to be controlled and traceable.

Blockchain could provide an additional record of when information was created, modified, or exchanged, creating a persistent transaction history for authorised participants.

The 2026 review estimated a 20–30% reduction in multi-site data reconciliation time. This could be particularly important in distributed manufacturing networks, where teams currently spend significant effort comparing records held in different systems.

The opportunity is therefore about storing more data and establishing greater confidence in the provenance of data moving between organisations.

Quality and compliance

Quality operations depend on reliable documentation and a defensible manufacturing history.

The latest review analysis found a 15–25% improvement in manufacturing and quality-control operational efficiency, alongside an estimated 30% reduction in compliance-documentation errors in blockchain-supported environments.

For manufacturers, the potential benefit is less about replacing existing quality systems and more about improving the connections between them.

Blockchain could act as a trusted record across systems operated by manufacturers, contract development, and manufacturing organisations, laboratories, suppliers, and logistics providers.

The real opportunity is interoperability, not simply decentralisation.

Image

Blockchain Could Connect the Whole Smart Factory

The strongest future case for blockchain in pharma manufacturing may emerge when it is combined with other technologies already entering pharmaceutical manufacturing.

IoT sensors can generate continuous information about equipment, environmental conditions, and processes; AI can analyse that information and identify anomalies or predict emerging problems; manufacturing execution systems can manage production activities, and laboratory and quality systems can maintain regulated records.

Blockchain could sit between these environments as a trusted data and provenance layer.

The 2026 review specifically examined blockchain’s integration with AI and IoT. It found that this combination can support real-time monitoring and predictive analytics, alongside the broader 30–55% operational-efficiency improvement and 25–50% reduction in logistics and compliance-related costs.

Therefore, rather than asking whether pharma should replace existing manufacturing infrastructure with blockchain, the more useful question may be:

Where could a trusted, shared data layer remove friction between the systems and organisations that already run the manufacturing network?

That is a considerably more practical position to start from.

Read The Looming Threat of Geopolitical Risk in Clinical Supply Chains

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Image

From Supply Chain Visibility To The Factory Floor

Much of the pharmaceutical blockchain discussion has focused on counterfeit medicines and supply-chain traceability.

The evidence supports that focus. The 2022 systematic review found counterfeit-drug prevention to be the most frequently studied application, appearing in 45% of the studies included.

But the technology’s potential impacts much more in pharma manufacturing.

Consider a distributed product network. One site produces an intermediate while another performs additional processing. A third conducts testing or packaging. Lastly, external laboratories, suppliers, and logistics providers may contribute further information.

Each participant needs confidence that the information received from the previous stage is reliable.

Blockchain could connect those events without necessarily requiring every participant to replace its existing infrastructure.

That is where the technology becomes most important.

Ultimately, blockchain in pharma manufacturing may ultimately be less about creating a new database and more about creating trusted provenance between existing digital systems.

For manufacturers operating in these complex distributed networks, this could determine whether blockchain becomes just another technology in the ether or a useful component of the digital manufacturing architecture already in use.

The Pharma Factory Floor Is the Hardest Test

The potential benefits of blockchain in pharma manufacturing are compelling, but implementation is considerably harder than the technology’s model suggests.

Pharmaceutical manufacturing is a highly regulated, validated process. Any technology that touches critical manufacturing, quality, or batch data must fit within established controls. As a result, blockchain cannot be treated like a conventional enterprise IT deployment.

Scalability, interoperability, data governance, regulatory harmonisation, and resource limitations all remain continuing barriers to adoption.

Blockchain may provide an immutable record, but pharma still needs to establish:

• who is permitted to generate recorded data;
• which data should be recorded;
• how identities are managed;
• how errors are corrected;
• how systems are validated;
• and who remains accountable when multiple organisations share the same infrastructure.

Immutability is not the same as data quality.

If erroneous information enters a blockchain, the technology does not determine that the information is wrong. The surrounding governance, validation, and source systems really matter.

Interoperability Could Decide the Success of Blockchain in Pharma Manufacturing

For manufacturers, the biggest opportunity may also be the biggest technical obstacle.

A typical pharmaceutical manufacturing network can include MES platforms, laboratory information management systems, enterprise resource planning systems, quality-management systems, equipment historians, IoT devices, supplier platforms, and contract manufacturing systems.

Replacing these systems with a single blockchain architecture would be neither practical nor desirable.

The more realistic model is integration.

The latest evidence suggests 20–30% reduction in multi-site data reconciliation time when blockchain is integrated with established computational and informatics systems.

That is potentially significant for global manufacturing networks.

A manufacturer operating across several facilities could use blockchain to establish a shared record of selected transactions while allowing each site to retain its validated operational systems.

The blockchain would therefore become a coordination layer rather than the manufacturing system itself. This would make adoption more feasible.

Validation and Regulatory Governance Are Most Important for Blockchain in Pharma Manufacturing

The pharmaceutical industry’s digital infrastructure is governed by requirements for data integrity, electronic records, system validation, cybersecurity, and controlled access.

Blockchain introduces additional questions, such as what happens when a record needs correction? Who controls the network? How are smart contracts validated? What happens if a participating organisation leaves the network? How are changes to the blockchain protocol governed?

These are not merely technical questions.

They are quality, compliance, and accountability questions.

Regulatory harmonisation and data governance are unresolved issues and standardised frameworks, scalable architectures, and modernised regulatory policies may support broader adoption.

That suggests a cautious implementation model. Blockchain should first be applied to well-defined, measurable problems, rather than introduced as a wholesale replacement for validated infrastructure.

Image

AI And IoT Could Make Blockchain More Useful

Blockchain works best when it operates alongside other technologies.

The 2026 review reported 30–55% improvements in operational efficiency and 25–50% reductions in logistics and compliance-related costs when blockchain is integrated with AI and IoT across the pharmaceutical workflows examined.

These figures should not be interpreted as guaranteed manufacturing returns, as they represent the review’s synthesis of the available literature.

Nevertheless, they point towards an important architectural possibility: AI can interpret data. IoT can generate it. Blockchain can help establish its provenance.

That combination could become increasingly relevant as pharmaceutical manufacturing moves towards continuous monitoring, predictive maintenance, digital twins, and more distributed production models.

The Counterfeit Medicine Problem Shows The Wider Potential

The case for blockchain also extends beyond the factory.

According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the global counterfeit drug market exceeds U.S. $200 billion annually and the research shows that blockchain could reduce counterfeit-medicine circulation by approximately 40%.

Blockchain-enabled traceability is also associated with more than 60% improvement in recall efficiency.

The earlier 2022 systematic review provides the most useful context. It assessed 38 pharmaceutical blockchain studies, with counterfeit-drug prevention appearing in 45% of them and tracking and tracing in 37%.

This suggests that traceability is not a peripheral blockchain application, and is the technology’s central pharmaceutical use.

For Technical Operations leaders, the opportunity is to connect that supply-chain capability with manufacturing data.

A batch could potentially acquire a persistent digital history from material origin through production, testing, release, distribution, and, if applicable, recall.

That is a much broader benefit than simply tracking a shipment.

How to Use Blockchain Best in Pharma Manufacturing

There should be no blanket recommendation to implement blockchain. Instead, manufacturers should identify specific points where multiple organisations need to establish trust in the same information.

The strongest candidates are likely to involve:

1. Cross-site data reconciliation where different systems must be compared.
2. Material and batch provenance across complex manufacturing networks.
3. Quality and compliance records involving multiple authorised parties.
4. Recall and traceability workflows where rapid identification matters.
5. Supplier and CMO coordination where information crosses organisational boundaries.

The business case should then be tested against measurable outcomes.

For example, a pilot could assess reconciliation time, investigation duration, documentation errors, data discrepancies, recall response, or manual quality activities before and after implementation.

That approach is more defensible than starting with the technology and searching for a use case afterwards.

Blockchain Is More Likely To Connect Pharma Than Replace It

The emerging evidence supports a measured conclusion for blockchain in pharma manufacturing.

Blockchain has a credible role in pharmaceutical manufacturing because the industry has a persistent need for trusted data exchange across organisational boundaries. The technology’s strongest potential lies in traceability, provenance, auditability, and interoperability.

But the barriers are substantial.

Pharma manufacturers cannot simply add blockchain to a validated environment and assume that compliance, data quality, or interoperability will follow. Governance, validation, cybersecurity, system integration, and regulatory expectations must be addressed from the beginning.

The most credible future is therefore not a blockchain-powered factory replacing today’s systems. It is a connected manufacturing ecosystem in which blockchain provides a trusted provenance layer between systems, sites, suppliers, and partners.

That could make blockchain a supporting technology for the next generation of digital Technical Operations rather than another isolated technology experiment.

For pharma leaders trying to decide whether blockchain can solve a specific manufacturing problem better than existing infrastructure, Pharmatica can provide the evidence and analysis to help decide.

We help Technical Operations professionals navigate fragmented data, multiple stakeholders, and traceability requirements to reduce operational friction. Our expert, evidence-led Insights help you understand targeted pilots, measurable outcomes, validated integrations, and clear governance.

The Pharmatica Chain Reaction is not about adopting technology for its own sake, but about connecting the technologies, data, and processes that make pharmaceutical manufacturing more resilient. Blockchain could become one part of that architecture, but its value will ultimately be measured by what it enables manufacturers to do better within existing frameworks.

Pharmatica: Insight. Connection. Impact.

Image